C1qA Protein

C1qA Protein

Overview

C1qA (Complement C1q A chain) is a structural subunit of the C1q complex, the first component of the classical complement cascade. Encoded by the C1QA gene on chromosome 1, C1qA protein serves as one of three polypeptide chains (A, B, and C) that compose the C1q macromolecule. C1q is a large, multimeric protein complex with a characteristic tulip-like structure, consisting of six heterotrimeric (A-B-C) subunits arranged around a central fibril-like core. The C1qA protein is synthesized primarily by macrophages, dendritic cells, and glial cells, particularly microglia in the central nervous system. As a key component of innate immune recognition, C1qA participates in pathogen recognition, immune complex clearance, and apoptotic cell removal—processes increasingly recognized as dysregulated in neurodegenerative diseases.

Function and Biology

The C1qA protein functions as a recognition and activation molecule in complement-mediated immunity. The C1q complex, including the C1qA subunit, binds to antibody-antigen complexes (particularly IgG and IgM) or directly to pathogen-associated molecular patterns and damage-associated molecular patterns (PAMPs and DAMPs). This binding triggers conformational changes that activate the C1r and C1s serine proteases, initiating the classical complement cascade. The cascade proceeds through a series of enzymatic amplifications, generating anaphylatoxins (C3a, C5a) and the membrane attack complex, which promote inflammation, complement receptor-mediated phagocytosis, and cell lysis.

C1qA Protein

Overview

C1qA (Complement C1q A chain) is a structural subunit of the C1q complex, the first component of the classical complement cascade. Encoded by the C1QA gene on chromosome 1, C1qA protein serves as one of three polypeptide chains (A, B, and C) that compose the C1q macromolecule. C1q is a large, multimeric protein complex with a characteristic tulip-like structure, consisting of six heterotrimeric (A-B-C) subunits arranged around a central fibril-like core. The C1qA protein is synthesized primarily by macrophages, dendritic cells, and glial cells, particularly microglia in the central nervous system. As a key component of innate immune recognition, C1qA participates in pathogen recognition, immune complex clearance, and apoptotic cell removal—processes increasingly recognized as dysregulated in neurodegenerative diseases.

Function and Biology

The C1qA protein functions as a recognition and activation molecule in complement-mediated immunity. The C1q complex, including the C1qA subunit, binds to antibody-antigen complexes (particularly IgG and IgM) or directly to pathogen-associated molecular patterns and damage-associated molecular patterns (PAMPs and DAMPs). This binding triggers conformational changes that activate the C1r and C1s serine proteases, initiating the classical complement cascade. The cascade proceeds through a series of enzymatic amplifications, generating anaphylatoxins (C3a, C5a) and the membrane attack complex, which promote inflammation, complement receptor-mediated phagocytosis, and cell lysis.

In the central nervous system, C1qA is constitutively expressed by microglia and perivascular macrophages, where it participates in synaptic pruning during development and maintaining normal synaptic architecture in adulthood. C1q binds to several ligands including immunoglobulin Fc regions, pentraxins, charged lipids, collectins, and specific complement receptors. The interaction between C1q and complement receptor 1 (CR1) on phagocytic cells facilitates the clearance of apoptotic cells and cellular debris—a process termed efferocytosis. Additionally, C1q can bind directly to neural cells through calreticulin and other receptors, modulating microglial activation and neuronal survival signaling independently of downstream complement cascade components.

Role in Neurodegeneration

Emerging evidence implicates C1qA dysfunction in multiple neurodegenerative pathologies. In Alzheimer's disease, C1qA expression is significantly elevated in microglial cells associated with amyloid plaques and tau tangles. The deposition of amyloid-beta aggregates appears to trigger C1q-mediated complement activation, leading to excessive synaptic elimination and neuronal loss. Transcriptomic studies of Alzheimer's disease brains reveal C1qA as part of a microglial activation signature associated with neuroinflammatory responses and cognitive decline.

In Parkinson's disease, C1qA-dependent complement activation contributes to alpha-synuclein-associated neurodegeneration. Aggregated alpha-synuclein activates microglia through pattern recognition receptors, inducing C1qA expression and complement-mediated neuronal injury. Similarly, in amyotrophic lateral sclerosis (ALS), C1qA expression correlates with motor neuron degeneration and disease progression, suggesting complement overactivation as a pathogenic mechanism.

Huntington's disease also features C1qA-mediated synaptic dysfunction, with abnormal C1q deposition near degenerating neurons. The hypermetabolic status and excitotoxicity characteristic of Huntington's disease may generate signals triggering C1q-mediated synaptic tagging and elimination.

Molecular Mechanisms

The neurotoxic effects of elevated C1qA involve both complement-dependent and complement-independent mechanisms. C1qA-mediated complement activation generates C3b deposition on synaptic terminals, marking them for elimination by complement receptors on microglia. The C1qA-C1r-C1s complex also generates anaphylatoxins that activate G-protein coupled receptors (C3aR and C5aR), amplifying microglial activation and pro-inflammatory cytokine production, including TNF-α, IL-1β, and IL-6.

Independently, C1q binding to calreticulin on neuronal surfaces triggers caspase-mediated apoptotic pathways without requiring downstream complement activation. This "complement-independent" signaling may occur through ER stress and calcium dysregulation.

Clinical and Research Significance

Targeting C1qA represents a promising therapeutic strategy for neurodegenerative diseases. Monoclonal antibodies against C1q and C3, as well as complement inhibitors targeting downstream components, are currently under investigation in preclinical and early clinical studies for Alzheimer's disease and other conditions. Understanding C1qA-driven neuroinflammation may facilitate development of neuroprotective therapies that selectively inhibit pathologic complement activation while preserving beneficial immune functions.

Related Entities

-